Does the media prefer BCRX or IONS?

In the previous week, Ionis Pharmaceuticals had 31 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 38 mentions for Ionis Pharmaceuticals and 7 mentions for BioCryst Pharmaceuticals. BioCryst Pharmaceuticals' average media sentiment score of 1.37 beat Ionis Pharmaceuticals' score of 0.82 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioCryst Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ionis Pharmaceuticals 18 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ALKS or BCRX?

In the previous week, Alkermes had 34 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 41 mentions for Alkermes and 7 mentions for BioCryst Pharmaceuticals. BioCryst Pharmaceuticals' average media sentiment score of 1.37 beat Alkermes' score of 0.60 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alkermes 14 Very Positive mention(s) 1 Positive mention(s) 13 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive BioCryst Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to BCRX or RGEN?

In the previous week, Repligen had 33 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 40 mentions for Repligen and 7 mentions for BioCryst Pharmaceuticals. BioCryst Pharmaceuticals' average media sentiment score of 1.37 beat Repligen's score of 1.01 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioCryst Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Repligen 21 Very Positive mention(s) 2 Positive mention(s) 11 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor LGND or BCRX?

In the previous week, Ligand Pharmaceuticals had 5 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 12 mentions for Ligand Pharmaceuticals and 7 mentions for BioCryst Pharmaceuticals. Ligand Pharmaceuticals' average media sentiment score of 1.41 beat BioCryst Pharmaceuticals' score of 1.37 indicating that Ligand Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ligand Pharmaceuticals 8 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioCryst Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BCRX or CLDX?

In the previous week, Celldex Therapeutics had 4 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 11 mentions for Celldex Therapeutics and 7 mentions for BioCryst Pharmaceuticals. BioCryst Pharmaceuticals' average media sentiment score of 1.37 beat Celldex Therapeutics' score of 0.96 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioCryst Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Celldex Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

BioCryst Pharmaceuticals (BCRX) Competitors

$8.80 -0.18 (-2.00%)

As of 01:35 PM Eastern

Compare

BCRX vs. IONS, ALKS, RGEN, LGND, and CLDX

Should you buy BioCryst Pharmaceuticals stock or one of its competitors? MarketBeat compares BioCryst Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BioCryst Pharmaceuticals include Ionis Pharmaceuticals (IONS), Alkermes (ALKS), Repligen (RGEN), Ligand Pharmaceuticals (LGND), and Celldex Therapeutics (CLDX). These companies are all part of the "biotechnology" industry.

How does BioCryst Pharmaceuticals compare to Ionis Pharmaceuticals?

BioCryst Pharmaceuticals (NASDAQ:BCRX) and Ionis Pharmaceuticals (NASDAQ:IONS) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

BioCryst Pharmaceuticals has a net margin of -51.71% compared to Ionis Pharmaceuticals' net margin of -64.76%. BioCryst Pharmaceuticals' return on equity of -76.36% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCryst Pharmaceuticals	-51.71%	-76.36%	60.12%
Ionis Pharmaceuticals	-64.76%	-111.08%	-17.41%

BioCryst Pharmaceuticals has higher earnings, but lower revenue than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than BioCryst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCryst Pharmaceuticals	$874.84M	2.56	$263.86M	-$1.78	N/A
Ionis Pharmaceuticals	$944M	9.42	-$381.39M	-$3.46	N/A

BioCryst Pharmaceuticals currently has a consensus price target of $20.80, suggesting a potential upside of 136.36%. Ionis Pharmaceuticals has a consensus price target of $94.65, suggesting a potential upside of 76.81%. Given BioCryst Pharmaceuticals' higher possible upside, equities analysts plainly believe BioCryst Pharmaceuticals is more favorable than Ionis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCryst Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.67
Ionis Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	18 Buy rating(s)	0 Strong Buy rating(s)	2.77

In the previous week, Ionis Pharmaceuticals had 31 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 38 mentions for Ionis Pharmaceuticals and 7 mentions for BioCryst Pharmaceuticals. BioCryst Pharmaceuticals' average media sentiment score of 1.37 beat Ionis Pharmaceuticals' score of 0.82 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioCryst Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ionis Pharmaceuticals	18 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Positive

BioCryst Pharmaceuticals has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market. Comparatively, Ionis Pharmaceuticals has a beta of 0.41, indicating that its stock price is 59% less volatile than the broader market.

85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. Comparatively, 93.9% of Ionis Pharmaceuticals shares are held by institutional investors. 3.8% of BioCryst Pharmaceuticals shares are held by insiders. Comparatively, 1.8% of Ionis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

BioCryst Pharmaceuticals beats Ionis Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does BioCryst Pharmaceuticals compare to Alkermes?

Alkermes (NASDAQ:ALKS) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both mid-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their media sentiment, earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.

Alkermes has a net margin of 3.96% compared to BioCryst Pharmaceuticals' net margin of -51.71%. Alkermes' return on equity of 4.15% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alkermes	3.96%	4.15%	2.19%
BioCryst Pharmaceuticals	-51.71%	-76.36%	60.12%

Alkermes presently has a consensus target price of $54.56, suggesting a potential upside of 8.98%. BioCryst Pharmaceuticals has a consensus target price of $20.80, suggesting a potential upside of 136.36%. Given BioCryst Pharmaceuticals' higher probable upside, analysts clearly believe BioCryst Pharmaceuticals is more favorable than Alkermes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alkermes	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.72
BioCryst Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.67

95.2% of Alkermes shares are owned by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. 4.6% of Alkermes shares are owned by insiders. Comparatively, 3.8% of BioCryst Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Alkermes has a beta of 0.34, suggesting that its share price is 66% less volatile than the broader market. Comparatively, BioCryst Pharmaceuticals has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market.

In the previous week, Alkermes had 34 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 41 mentions for Alkermes and 7 mentions for BioCryst Pharmaceuticals. BioCryst Pharmaceuticals' average media sentiment score of 1.37 beat Alkermes' score of 0.60 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alkermes	14 Very Positive mention(s)	1 Positive mention(s)	13 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
BioCryst Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioCryst Pharmaceuticals has lower revenue, but higher earnings than Alkermes. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alkermes	$1.48B	5.69	$241.66M	$0.38	131.76
BioCryst Pharmaceuticals	$874.84M	2.56	$263.86M	-$1.78	N/A

Summary

Alkermes beats BioCryst Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

How does BioCryst Pharmaceuticals compare to Repligen?

BioCryst Pharmaceuticals (NASDAQ:BCRX) and Repligen (NASDAQ:RGEN) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, media sentiment, earnings, risk, institutional ownership and valuation.

BioCryst Pharmaceuticals currently has a consensus price target of $20.80, indicating a potential upside of 136.36%. Repligen has a consensus price target of $166.43, indicating a potential upside of 14.32%. Given BioCryst Pharmaceuticals' higher possible upside, analysts plainly believe BioCryst Pharmaceuticals is more favorable than Repligen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCryst Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.67
Repligen	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	2.94

Repligen has a net margin of 5.29% compared to BioCryst Pharmaceuticals' net margin of -51.71%. Repligen's return on equity of 5.30% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCryst Pharmaceuticals	-51.71%	-76.36%	60.12%
Repligen	5.29%	5.30%	3.79%

BioCryst Pharmaceuticals has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market. Comparatively, Repligen has a beta of 1.03, indicating that its share price is 3% more volatile than the broader market.

In the previous week, Repligen had 33 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 40 mentions for Repligen and 7 mentions for BioCryst Pharmaceuticals. BioCryst Pharmaceuticals' average media sentiment score of 1.37 beat Repligen's score of 1.01 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioCryst Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Repligen	21 Very Positive mention(s)	2 Positive mention(s)	11 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. Comparatively, 97.6% of Repligen shares are held by institutional investors. 3.8% of BioCryst Pharmaceuticals shares are held by insiders. Comparatively, 0.6% of Repligen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

BioCryst Pharmaceuticals has higher revenue and earnings than Repligen. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCryst Pharmaceuticals	$874.84M	2.56	$263.86M	-$1.78	N/A
Repligen	$738.26M	11.13	$48.89M	$0.73	199.42

Summary

Repligen beats BioCryst Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does BioCryst Pharmaceuticals compare to Ligand Pharmaceuticals?

Ligand Pharmaceuticals (NASDAQ:LGND) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

Ligand Pharmaceuticals currently has a consensus target price of $326.00, suggesting a potential upside of 13.39%. BioCryst Pharmaceuticals has a consensus target price of $20.80, suggesting a potential upside of 136.36%. Given BioCryst Pharmaceuticals' higher probable upside, analysts plainly believe BioCryst Pharmaceuticals is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ligand Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88
BioCryst Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.67

Ligand Pharmaceuticals has a net margin of 55.95% compared to BioCryst Pharmaceuticals' net margin of -51.71%. Ligand Pharmaceuticals' return on equity of 16.19% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ligand Pharmaceuticals	55.95%	16.19%	11.13%
BioCryst Pharmaceuticals	-51.71%	-76.36%	60.12%

In the previous week, Ligand Pharmaceuticals had 5 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 12 mentions for Ligand Pharmaceuticals and 7 mentions for BioCryst Pharmaceuticals. Ligand Pharmaceuticals' average media sentiment score of 1.41 beat BioCryst Pharmaceuticals' score of 1.37 indicating that Ligand Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ligand Pharmaceuticals	8 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioCryst Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioCryst Pharmaceuticals has higher revenue and earnings than Ligand Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ligand Pharmaceuticals	$268.09M	21.49	$124.45M	$7.37	39.01
BioCryst Pharmaceuticals	$874.84M	2.56	$263.86M	-$1.78	N/A

91.3% of Ligand Pharmaceuticals shares are held by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. 5.6% of Ligand Pharmaceuticals shares are held by insiders. Comparatively, 3.8% of BioCryst Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Ligand Pharmaceuticals has a beta of 1.13, indicating that its share price is 13% more volatile than the broader market. Comparatively, BioCryst Pharmaceuticals has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market.

Summary

Ligand Pharmaceuticals beats BioCryst Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does BioCryst Pharmaceuticals compare to Celldex Therapeutics?

BioCryst Pharmaceuticals (NASDAQ:BCRX) and Celldex Therapeutics (NASDAQ:CLDX) are both mid-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, media sentiment, profitability, institutional ownership and risk.

BioCryst Pharmaceuticals has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than BioCryst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCryst Pharmaceuticals	$874.84M	2.56	$263.86M	-$1.78	N/A
Celldex Therapeutics	$865K	3,438.22	-$258.76M	-$4.26	N/A

Celldex Therapeutics has a net margin of 0.00% compared to BioCryst Pharmaceuticals' net margin of -51.71%. Celldex Therapeutics' return on equity of -50.72% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCryst Pharmaceuticals	-51.71%	-76.36%	60.12%
Celldex Therapeutics	N/A	-50.72%	-46.59%

BioCryst Pharmaceuticals has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market. Comparatively, Celldex Therapeutics has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market.

85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. 3.8% of BioCryst Pharmaceuticals shares are held by company insiders. Comparatively, 5.2% of Celldex Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Celldex Therapeutics had 4 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 11 mentions for Celldex Therapeutics and 7 mentions for BioCryst Pharmaceuticals. BioCryst Pharmaceuticals' average media sentiment score of 1.37 beat Celldex Therapeutics' score of 0.96 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioCryst Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Celldex Therapeutics	7 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioCryst Pharmaceuticals currently has a consensus target price of $20.80, indicating a potential upside of 136.36%. Celldex Therapeutics has a consensus target price of $54.62, indicating a potential upside of 44.14%. Given BioCryst Pharmaceuticals' higher probable upside, analysts plainly believe BioCryst Pharmaceuticals is more favorable than Celldex Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCryst Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.67
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

Summary

Celldex Therapeutics beats BioCryst Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

Get BioCryst Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BCRX vs. The Competition

Export

Metric	BioCryst Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.24B	$3.51B	$6.80B	$12.67B
Dividend Yield	N/A	3.78%	2.59%	10.03%
P/E Ratio	-4.94	7.37	282.15	25.05
Price / Sales	2.56	1,199.53	571.19	79.42
Price / Cash	7.25	44.80	28.64	34.82
Price / Book	-15.44	16.86	11.03	6.18
Net Income	$263.86M	-$12.56M	$3.49B	$347.72M
7 Day Performance	-8.14%	-1.04%	0.31%	0.64%
1 Month Performance	-10.57%	-7.80%	-4.41%	-3.82%
1 Year Performance	10.69%	48.79%	62.76%	20.08%

BioCryst Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BCRX BioCryst Pharmaceuticals	3.7582 of 5 stars	$8.80 -2.0%	$20.80 +136.4%	+13.0%	$2.24B	$874.84M	N/A	530	Positive News Upcoming Earnings Short Interest Decrease
IONS Ionis Pharmaceuticals	3.8095 of 5 stars	$55.96 -1.0%	$95.90 +71.4%	+20.3%	$9.35B	$944M	N/A	1,402	Analyst Downgrade Insider Trade
ALKS Alkermes	2.9246 of 5 stars	$52.73 -0.3%	$52.50 -0.4%	+84.5%	$8.82B	$1.48B	58.59	2,050	News Coverage Analyst Revision
RGEN Repligen	4.0472 of 5 stars	$131.06 -0.7%	$165.36 +26.2%	+18.6%	$7.44B	$738.26M	145.62	2,000	Positive News Earnings Report
LGND Ligand Pharmaceuticals	4.5853 of 5 stars	$297.50 -1.0%	$319.00 +7.2%	+116.7%	$6.02B	$268.09M	40.37	80	Positive News Upcoming Earnings Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BCRX) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioCryst Pharmaceuticals (BCRX) Competitors

BCRX vs. IONS, ALKS, RGEN, LGND, and CLDX

How does BioCryst Pharmaceuticals compare to Ionis Pharmaceuticals?

Summary

How does BioCryst Pharmaceuticals compare to Alkermes?

Summary

How does BioCryst Pharmaceuticals compare to Repligen?

Summary

How does BioCryst Pharmaceuticals compare to Ligand Pharmaceuticals?

Summary

How does BioCryst Pharmaceuticals compare to Celldex Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCRX vs. The Competition

BioCryst Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioCryst Pharmaceuticals (BCRX) Competitors

BCRX vs. IONS, ALKS, RGEN, LGND, and CLDX

How does BioCryst Pharmaceuticals compare to Ionis Pharmaceuticals?

Is BCRX or IONS more profitable?

Which has stronger valuation and earnings, BCRX or IONS?

Do analysts rate BCRX or IONS?

Does the media prefer BCRX or IONS?

Which has more volatility & risk, BCRX or IONS?

Do insiders and institutionals hold more shares of BCRX or IONS?

Summary

How does BioCryst Pharmaceuticals compare to Alkermes?

Is ALKS or BCRX more profitable?

Do analysts recommend ALKS or BCRX?

Do institutionals & insiders hold more shares of ALKS or BCRX?

Which has more volatility & risk, ALKS or BCRX?

Does the media favor ALKS or BCRX?

Which has preferable earnings and valuation, ALKS or BCRX?

Summary

How does BioCryst Pharmaceuticals compare to Repligen?

Do analysts prefer BCRX or RGEN?

Is BCRX or RGEN more profitable?

Which has more volatility & risk, BCRX or RGEN?

Does the media refer more to BCRX or RGEN?

Do institutionals and insiders have more ownership in BCRX or RGEN?

Which has better earnings & valuation, BCRX or RGEN?

Summary

How does BioCryst Pharmaceuticals compare to Ligand Pharmaceuticals?

Do analysts prefer LGND or BCRX?

Is LGND or BCRX more profitable?

Does the media favor LGND or BCRX?

Which has stronger earnings & valuation, LGND or BCRX?

Do institutionals and insiders hold more shares of LGND or BCRX?

Which has more risk and volatility, LGND or BCRX?

Summary

How does BioCryst Pharmaceuticals compare to Celldex Therapeutics?

Which has preferable valuation & earnings, BCRX or CLDX?

Is BCRX or CLDX more profitable?

Which has more volatility and risk, BCRX or CLDX?

Do institutionals & insiders have more ownership in BCRX or CLDX?

Does the media prefer BCRX or CLDX?

Do analysts prefer BCRX or CLDX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCRX vs. The Competition

BioCryst Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools